HK Stock Market Move | LIVZON PHARMA (01513) rose nearly 3% as the Lecanemab injection has recently been officially approved.

date
14:23 07/09/2026
avatar
GMT Eight
Livzon Pharmaceutical (01513) rose nearly 3%, and as of the time of publication, it was up 2.55%, priced at HKD 20.9, with a transaction volume of HKD 15.2846 million.
LIVZON PHARMA (01513) rose nearly 3%, as of the time of writing, it increased by 2.55%, trading at HKD 20.9 with a transaction volume of HKD 15.2846 million. On the news front, recently, according to LIVZON PHARMA's official WeChat account, the companys first IL-17A/F dual-target innovative biological agent, Libaotan (generic name: Lakanqita monoclonal antibody injection), has officially been approved for market launch. Guosen pointed out that Lakanqita monoclonal antibody (IL-17A/F antibody) showed superior efficacy compared to Secukinumab in head-to-head comparisons for psoriasis indications, and the Phase 3 clinical study for ankylosing spondylitis indications achieved good results.